Evidence map›Paper›PMID 33889522›Full record

ArticleTranslational lung cancer research2021

circFBXW7 attenuates malignant progression in lung adenocarcinoma by sponging miR-942-5p.

Yanting Dong, Tong Qiu, Yunpeng Xuan, Ao Liu, Xiao Sun, Zhangfeng Huang, Wenhao Su, Wenxing Du, Tianxiang Yun, Yang Wo and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Hsa_circ_0129047 sponges miR-665 to attenuate lung adenocarcinoma progression by upregulating protein tyrosine phosphatase receptor type B.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Yanting DongDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Tong QiuDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Yunpeng XuanDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Ao LiuDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Xiao SunDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Zhangfeng HuangDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Wenhao SuDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Wenxing DuDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Tianxiang YunDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Yang WoDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Alfons NavarroMolecular Oncology and Embryology Laboratory, Human Anatomy Unit, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
Wenjie JiaoDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Affiliated Hospital of Qingdao University · CNQingdao University · CNUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs a type of non-coding RNA, circular RNAs (circRNAs) are considered to be functional molecules associated with human cancers. An increasing number of circRNAs have been verified in malignant progression in a number of cancers. The circRNA, circFBXW7, has been proven to play an important role in tumor proliferation and metastasis. However, whether circFBXW7 influences progression in lung adenocarcinoma (LUAD) remains unclear.

methodsQuantitative real-time reverse transcriptase PCR (qRT-PCR) was used to verify circFBXW7 in LUAD cell lines and LUAD tissues. Kaplan-Meier analysis was then used to compare the disease-free survival (DFS) and overall survival (OS) of these LUAD patients. The biological function of circFBXW7 was examined by overexpression and knockdown of circFBXW7 using MTT assay, EdU assay, wound-healing assay, and Transwell

resultscircFBXW7 was downregulated in LUAD cell lines and tissues, and LUAD patients with lower levels had shorter DFS and OS. The

conclusionsOur findings showed that circFBXW7 inhibits proliferation and migration by controlling the miR-942-5p/BARX2 axis in LUAD cell lines and its levels correlates with patient survival suggesting that regulating circFBXW7 could have therapeutic value in treating LUAD patients.

Indexed as

BARX2circFBXW7epithelial-mesenchymal transition (EMT)lung adenocarcinoma (LUAD)miR-942-5pmiRNA sponge

Identifiers

PMID33889522
PMCPMC8044477
OpenAlexW3152006103

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.